- Conditions
- Meningococcal Disease
- Interventions
- MenACWY-CRM
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 11 Years to 21 Years
- Enrollment
- 55,397 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 2,628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clostridium Infections
- Interventions
- GS-CDA1/MDX-1388, normal saline
- Biological
- Lead sponsor
- MassBiologics
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 22
- States / cities
- Los Angeles, California • Oakland, California • Newark, Delaware + 18 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 2 Months to 2 Months
- Enrollment
- 4,545 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 53
- States / cities
- Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
- Conditions
- Otomycosis
- Interventions
- SVT-15652, Placebo
- Drug
- Lead sponsor
- Salvat
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Orangeburg, South Carolina
- Conditions
- Cystic Fibrosis
- Interventions
- Throat Swab
- Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 1 Day to 3 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- Mindfulness-Based Stress Reduction
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Anthrax
- Interventions
- AV7909, BioThrax
- Biological
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 4
- States / cities
- Miami, Florida • Mt. Pleasant, South Carolina • New Braunfels, Texas + 1 more
- Conditions
- Uncomplicated Urogenital Gonorrhea
- Interventions
- solithromycin, ceftriaxone, azithromycin
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio
- Conditions
- Pseudomonas Aeruginosa Pneumonia
- Interventions
- AR-105, Placebo
- Drug
- Lead sponsor
- Aridis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 14
- States / cities
- Sacramento, California • San Diego, California • Jacksonville, Florida + 9 more
- Conditions
- Tuberculosis
- Interventions
- Moxifloxacin, Isoniazid
- Drug
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2007
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 3 more
- Conditions
- Bacterial Conjunctivitis
- Interventions
- gatifloxacin, moxifloxacin 0.5% eye drops
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- Up to 31 Days
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- HIV Infections
- Interventions
- Sulfamethoxazole-Trimethoprim, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Syphilis
- Interventions
- Abbott Laboratories Determine test for syphilis, Investigational syphilis immunochromatographic strip test
- Device
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2009
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 2 more
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 2 more
- Conditions
- Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
- Interventions
- Oral Encochleated Amphotericin B (CAMB), Fluconazole
- Drug
- Lead sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Lymphoma, Small Intestine Cancer
- Interventions
- visilizumab
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Meningococcal Infections
- Interventions
- MenACWY-CRM, Licensed meningococcal ACWY vaccine
- Biological
- Lead sponsor
- Novartis Vaccines
- Industry
- Eligibility
- 2 Years to 10 Years
- Enrollment
- 2,907 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 52
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Downey, California + 39 more
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- cyclophosphamide, fludarabine phosphate, tacrolimus, mycophenolate mofetil, polymerase chain reaction, fluorescence in situ hybridization, polymorphism analysis, gene expression analysis, total-body irradiation, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
- Drug · Genetic · Radiation + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2014
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Pneumococcal Infections
- Interventions
- Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
- Conditions
- Campylobacter Infections
- Interventions
- Campylobacter jejuni strain CG8421
- Biological
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Silver Spring, Maryland • Burlington, Vermont
- Conditions
- Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides
- Interventions
- Mogamulizumab, Brentuximab vedotin
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Onychomycosis of Toenails
- Interventions
- AN2690 Topical Solution, 5%, Solution Vehicle
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Burbank, California + 23 more